CLINICAL AND HORMONAL HEALTH OF CHILDREN AGED 6–12 YEARS BORN FROM PREGNANCIES INDUCED BY DOPAMINE AGONISTS
Keywords:
hyperprolactinemia, prolactinoma, dopamine agonists, pregnancy, children, hormonal health.Abstract
Relevance:Hyperprolactinemia and prolactin-secreting pituitary adenomas are among the leading endocrine causes of impaired reproductive function in women. Dopamine agonists, such as bromocriptine and cabergoline, are widely used to normalize prolactin levels, restore ovulatory function, and achieve pregnancy. Despite their proven clinical efficacy and relative safety, the long-term effects of prenatal exposure to dopamine agonists on the clinical and hormonal health of offspring remain insufficiently studied. The age of 6–12 years is of particular interest, as this period is characterized by active growth and the formation of neuroendocrine regulation. Purpose: To analyze current literature data on the clinical, somatic, and hormonal status of children aged 6–12 years born from pregnancies induced by dopamine agonists. Materials and methods: An analytical review of domestic and international scientific publications devoted to hyperprolactinemia, prolactinomas, the use of dopamine agonists during pregnancy planning and early gestation, as well as the assessment of physical development and hormonal profiles of children exposed to these drugs prenatally, was conducted. Results: Most studies report no significant disturbances in physical development or marked hormonal abnormalities in children born to mothers treated with dopamine agonists. However, available data regarding endocrine system status in school-aged children are limited, and comparative studies with control groups are scarce.
Conclusion: The issue of long-term clinical and hormonal effects of prenatal exposure to dopamine agonists remains relevant and requires further comprehensive research.
References
Aashikaa J. K., Mirkhmidova S. M. Prolactinoma in pregnancy and its treatment // Endokrinologiyaning dolzarb muammolari: Xalqaro ilmiy-amaliy anjumani materiallari to‘plami. – Toshkent: MChJ «Tibbiyot nashriyoti matbaa uyi», 2023. – P. 43.
Araujo B., Belo S., Carvalho D. Pregnancy and tumor outcomes in women with prolactinoma
// Hormone Research in Paediatrics. – 2023. – DOI: 10.1055/s-0043-112861.
Carvalho Santos A., Yela D. A., Nakamura R. M., et al. Does hyperprolactinemia treatment affect pregnancy and perinatal outcomes? // Archives of Endocrinology and Metabolism. – 2024. – PMID: 39536251.
Colao A., Abs R., Gonzalez-Barcena D., et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study // Clinical Endocrinology. – 2007. – DOI: 10.1111/j.1365-2265.2007.03000.x.
De Wit W., Coelingh Bennink H. J. T. Prophylactic bromocriptine treatment during pregnancy in women with macroprolactinomas // British Journal of Obstetrics and Gynaecology. – 1984. – DOI: 10.1111/j.1471-0528.1984.tb15076.x.
Dosanova A. K. Quality of life of patients with prolactinomas after various treatment methods
// Biomeditsina va amaliyot jurnali. – 2020. – №1. – P. 85–95.
Dosanova A. K., Bazarbekova R. B. Experience of conservative treatment of women with prolactinomas // Biomeditsina va amaliyot jurnali. – 2020. – №1. – P. 96–101.
Halimiova Z. Yu., Safarova M. S., Gumarova A. A., Jabborova G. M. Clinic and course of hyperprolactinemia in prolactinomas // Biomeditsina va amaliyot jurnali. – 2020. – SI 1. – P. 69–78.
Halimiova Z. Yu., Issaeva S. S. Pituitary adenomas: from diagnosis to therapy (review) // Vestnik assotsiatsii pulmonologov Tsentralnoy Azii. – 2024. – Vol. 2, №4. – P. 59–70.
Halimiova Z. Yu., et al. Evaluation of cabergoline efficacy in prolactinomas // Pediatriya. – 2018. – №2. – P. 144–147.
Halimiova Z. Yu., et al. Prolactinoma: clinical and diagnostic aspects // Pediatriya. – 2018. –
№2. – P. 140–144.
Halimiova Z. Yu., et al. Influence of cabergoline on metabolic syndrome in prolactin-secreting pituitary adenomas // Journal of Theoretical and Clinical Medicine. – 2017. – №6. – P.
–32.
Maiter D. Prolactinoma and pregnancy: from the wish of conception to lactation // Annales d’Endocrinologie. – 2016. – DOI: 10.1016/j.ando.2016.04.001.
Nasyrоva H. K. Features of pregnancy course in women with prolactinomas // Journal of Theoretical and Clinical Medicine. – 2018. – №5. – P. 92–96.
Nasyrоva H. K. Management of pregnant women with prolactinomas and pregnancy outcomes // Journal of Theoretical and Clinical Medicine. – 2019. – №3. – P. 107–110.
Nasyrоva H. K., Mukhammedaminova D. T., Halimiova Z. Yu. Epidemiology and management problems of prolactinomas // Biomeditsina va amaliyot jurnali. – 2020. – SI 1. –
P. 163–171.
O’Sullivan S. M., Farrant M. T., Ogilvie C. M., et al. Pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists // Australian and New Zealand Journal of Obstetrics and Gynaecology. – 2019. – DOI: 10.1111/ajo.13070.
Otis A.-S., Brochet M.-S., Tremblay Z., et al. Cabergoline use and pregnancy outcomes: a systematic review // Birth Defects Research. – 2025. – DOI: 10.1002/bdr2.2464.
Prencipe N., Bona C., Cuboni D., et al. Prolactin-secreting tumors, dopamine agonists and pregnancy // Journal of Endocrinological Investigation. – 2024. – PMID: 38499816.
Raymond J. P., Goldstein E., Konopka P., et al. Follow-up of children born of bromocriptine-treated mothers // Hormone Research. – 1985. – DOI: 10.1159/000180100.
Stalldecker G., Mallea-Gil M. S., Guitelman M., et al. Effects of cabergoline on pregnancy and embryo-fetal development // Pituitary. – 2010. – DOI: 10.1007/s11102-010-0243-6.
Shupik P. L., Roshchina G. F. Hyperprolactinemia and its consequences: modern concepts // Medical Express. – 2018. – №5. – P. 66.
